Bertilimumab
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function. It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders. iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.
Link from a Wikipage to another Wikipage
primaryTopic
Bertilimumab
Bertilimumab is a human monoclonal antibody that binds to eotaxin-1, an important regulator of overall eosinophil function. It was discovered by Cambridge Antibody Technology using their phage display technology. Named CAT-213 during early discovery and development by CAT, it was to be used to treat severe allergic disorders. iCo Therapeutics Inc. renamed the drug from CAT-213 to iCo-008 and, at that stage, planned to initiate a Phase II clinical trial in patients with vernal keratoconjunctivitis.
has abstract
Bertilimumab is a human monocl ...... ntained a high antibody yield.
@en
برتيليموماب هو جسم مضاد وحيد ا ...... اء كرون إضافة لاستخدامات أخرى.
@ar
CAS number
375348-49-5
FDA UNII code
60879E4NED
Wikipage page ID
page length (characters) of wiki page
Wikipage revision ID
977,977,326
Link from a Wikipage to another Wikipage
ATC prefix
none
@en
CAS number
ChemSpiderID
none
@en
mab type
mab
@en
source
u
@en
target
type
mab
@en
UNII
608,790,000
Verifiedfields
changed
@en
verifiedrevid
459,958,463
wikiPageUsesTemplate
subject
hypernym
comment
Bertilimumab is a human monocl ...... h vernal keratoconjunctivitis.
@en
برتيليموماب هو جسم مضاد وحيد ا ...... اء كرون إضافة لاستخدامات أخرى.
@ar
label
Bertilimumab
@en
برتيليموماب
@ar